Publications by authors named "L Algeri"
Article Synopsis
- * A study analyzed 165 stage IV SI-NET patients between 2015 and 2021, revealing that 25% developed CHD, particularly moderate-to-severe tricuspid insufficiency, and had a median OS of 4.5 years after CHD diagnosis.
- * The research highlights the importance of screening and monitoring for CHD in patients with CS, as CHD significantly worsens prognosis, with a hazard ratio for OS
Article Synopsis
- Immune checkpoint inhibitors (ICIs) are special medicines that help treat certain types of stomach and intestine cancers that have specific gene problems (dMMR/MSI-H).
- These medicines have shown great results, letting doctors skip using some harsh treatments like chemotherapy and surgery for some patients.
- However, scientists are still figuring out how well they work for other types of cancers and are studying how to find the right patients who can benefit the most from these new treatments.
Promising targetable biomarkers in pancreatic neuroendocrine tumours.
Expert Rev Endocrinol Metab
November 2023
Introduction: In the treatment scenario of PanNETs-targeted therapies are desired but limited, as rarity and heterogeneity on PanNETs pose limitations to their development.
Areas Covered: We performed a literature review searching for promising druggable biomarkers and potential treatments to be implemented in the next future. We focused on treatments which have already reached clinical experimentation, although in early phases.
Background: The patient selection for optimal adjuvant therapy in gastrointestinal stromal tumors (GISTs) is provided by nomogram based on tumor size, mitotic index, tumor location, and tumor rupture. Although mutational status is not currently used to risk assessment, tumor genotype showed a prognostic influence on natural history and tumor relapse. Innovative measures, such as KIT/PDGFRA-mutant-specific variant allele frequency (VAF) levels detection from next-generation sequencing (NGS), may act as a surrogate of tumor burden and correlate with prognosis and overall survival of patients with GIST, helping the choice for adjuvant treatment.
View Article and Find Full Text PDF